Company Information

  

Address: 409 ILLINOIS STREET  
City: SAN FRANCISCO 
State: CA 
Zip Code: 94158 
Telephone: 415-978-1200 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a science-based biopharmaceutical company discovering and developing first-in-class therapeutics. Roxadustat (FG-4592), our most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase ("HIF-PH") activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor ("CTGF"), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer, and Duchenne muscular dystrophy ("DMD"). We have taken a global approach to the development and future commercialization of our product candidates, which includes development and commercialization in the People's Republic of China ("China").  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.75NAN/E
12/2017-1.73NAN/E
09/2017-2.03NAN/E
06/2017-1.91NAN/E
03/2017-1.05NAN/E
12/2016-0.98NAN/E
09/2016-1.29NAN/E
06/2016-1.63NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.11Total Liab/Total Assets0.37
Net Inc/Total Assets-0.14Total Liab/Inv Cap0.41
Net Inc/Inv Cap-0.15Total Liab/Comm Equity0.29
Pretax Inc/Net Sales-1.00Interest Coverage Ratio-11.97
Net Inc/Net Sales-1.00Curr Debt/EquityNA
Cash Flow/Net Sales-0.53LTD/Equity0.17
SG&A/NetSales0.41Total Debt/Equity0.17
Asset Utilization   Liquidity  
Net Receivables Turnover13.30Quick Ratio9.69
Inventory TurnoverNACurrent Ratio9.69
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.19Inv/Curr AssetsNA
Net Sales/PP&E0.97  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 31.93 42.51 27.27 26.45
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 15.55 13.85 12.95 13.43
Operating Income -40.60 -23.81 -36.02 -33.96
Interest Exp 2.77 1.81 2.77 2.76
Pretax Income -41.30 -21.97 -37.68 -35.69
Other Income 2.07 3.65 1.11 1.03
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -41.40 -22.12 -37.74 -35.73

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 703.77 735.72 729.97 359.40
Receivables - Total 9.98 8.45 8.63 8.93
Inventories - Total NA NA NA NA
Total Current Assets 717.16 748.97 741.46 371.34
Net Property, Plant & Equipment 129.88 129.48 126.64 122.59
Total Assets 867.61 898.65 894.89 542.64
Liabilities        
Accounts Payable 66.41 69.29 60.52 51.80
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 83.34 77.26 68.50 59.77
Long-Term Debt 97.62 97.76 97.37 97.45
Total Liabilities 368.09 335.47 323.39 312.54
Stockholder's Equity        
Minority Interest 19.27 19.27 19.27 19.27
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.83 0.83 0.82 0.71
Retained Earnings -670.80 -595.95 -573.82 -536.09
Treasury Stock NA NA NA NA
Total Stockholders' Equity 499.52 563.18 571.50 230.10
Total Liabilities and Stockholders' Equity 867.61 898.65 894.89 542.64

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -31.96 -1.19 -18.43 -19.76
Net Cash Provided by Investing Activities 15.30 20.00 9.54 16.92
Net Cash Provided by Financing Activities 2.05 3.41 370.03 122.46

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/2013102.17-14.94--
12/2014137.60-59.50-3.17
12/2015180.83-85.78-1.42
12/2016179.58-61.68-0.98
12/2017125.67-126.20-1.73
Growth Rates5.31----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1822453,53864.10




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.